Oxford University and Novo Nordisk invest $143m in diabetes partnership

The University of Oxford and Denmark-based Novo Nordisk have entered into a DKr1 billion ($143 million) research collaboration focusing on type 2 diabetes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novartis scores UK win in high-stakes Entresto fight

14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.

Pharma

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

12 August 2026 Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.

Pharma

Lilly mounts defence as generics circle Mounjaro and Zepbound

11 August 2026 A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.

More features

Novartis scores UK win in high-stakes Entresto fight

Invisalign maker secures first China win against clear aligner rival

Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

Lilly mounts defence as generics circle Mounjaro and Zepbound

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

Kirkland clears conflicts hurdle in trade secrets spat

Oxford University and Novo Nordisk invest $143m in diabetes partnership

More on this story

Editor's picks

Editor's picks

More features